Business Description
BioInvent International AB
ISIN : SE0015244520
Total Employee Number:
112Compare
Compare
Traded in other countries / regions
BINV.Sweden0H22.UKBIX.GermanyBOVNF.USA IPO Date
2016-05-13Description
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 72.98 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 9.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.4 | |||||
3-Year EBITDA Growth Rate | -120.8 | |||||
3-Year EPS without NRI Growth Rate | -94.3 | |||||
3-Year FCF Growth Rate | -64.5 | |||||
3-Year Book Growth Rate | -30 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.32 | |||||
Quick Ratio | 5.2 | |||||
Cash Ratio | 4.8 | |||||
Days Sales Outstanding | 76.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 0.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -160.73 | |||||
Net Margin % | -153.69 | |||||
EBITDA Margin % | -151.73 | |||||
FCF Margin % | -121.96 | |||||
OCF Margin % | -119.61 | |||||
ROE % | -51.35 | |||||
ROA % | -44.39 | |||||
ROIC % | -278.37 | |||||
3-Year ROIIC % | 51.82 | |||||
ROC (Joel Greenblatt) % | -954.82 | |||||
ROCE % | -53.48 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 3.57 | |||||
PS Ratio | 7.71 | |||||
PB Ratio | 3.83 | |||||
Price-to-Tangible-Book | 3.83 | |||||
EV-to-EBIT | -3.25 | |||||
EV-to-Forward-EBIT | 3.91 | |||||
EV-to-EBITDA | -3.43 | |||||
EV-to-Forward-EBITDA | 3.6 | |||||
EV-to-Revenue | 5.21 | |||||
EV-to-Forward-Revenue | 31.59 | |||||
EV-to-FCF | -4.63 | |||||
Price-to-GF-Value | 0.52 | |||||
Price-to-Median-PS-Value | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 4.1 | |||||
| Price-to-Net-Cash | 4.66 | |||||
Earnings Yield (Greenblatt) % | -30.8 | |||||
FCF Yield % | -16.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
BioInvent International AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 217.858 | ||
| EPS (TTM) (kr) | -5.09 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -54.52 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (kr) | - | ||
| 20-Day SMA (kr) | 34.75 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (kr) | 34.75 - 34.75 | ||
| Shares Outstanding (Mil) | 65.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioInvent International AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioInvent International AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-29 | In 113 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 113 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-27 | In 50 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 | In 50 days | ||
| Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer | 2026-05-27 08:00 | 34.75 (+0.00%) | ||
| General meeting for 2025 | 2026-04-29 16:00 | 34.75 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 | 34.75 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 34.75 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 34.75 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 14:00 | 34.75 (+0.00%) |
Show
Entries
BioInvent International AB Frequently Asked Questions
What is BioInvent International AB(CHIX:BINVs)'s stock price today?
The current price of CHIX:BINVs is kr34.75. The 52 week high of CHIX:BINVs is kr34.75 and 52 week low is kr34.75.
When is next earnings date of BioInvent International AB(CHIX:BINVs)?
The next earnings date of BioInvent International AB(CHIX:BINVs) is 2026-08-27.
Does BioInvent International AB(CHIX:BINVs) pay dividends? If so, how much?
BioInvent International AB(CHIX:BINVs) does not pay dividend.
Press Release
Articles on BioInvent International AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers